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5-Aminoisoquinolinone reduces renal injury and dysfunction
caused by experimental ischemia/reperfusion.
Background. Poly (ADP-ribose) polymerase (PARP), a nu-
clear enzyme activated by strand breaks in DNA, plays an
important role in the development of ischemia/reperfusion
(I/R) injury. The aim of this study was to investigate
the effects of a water-soluble and potent PARP inhibitor,
5-aminoisoquinolinone (5-AIQ), on the renal injury and dys-
function caused by oxidative stress of the rat kidney in vitro
and in vivo.
Methods. Primary cultures of rat renal proximal tubular
cells, subjected to oxidative stress caused by hydrogen perox-
ide (H2O2), were incubated with increasing concentrations of
5-AIQ (0.01 to 1 mmol/L) after which PARP activation, cellular
injury, and cell death were measured. In in vivo experiments,
anesthetized male Wistar rats were subjected to renal bilateral
ischemia (45 minutes) followed by reperfusion (6 hours) in the
absence or presence of 5-AIQ (0.3 mg/kg) after which renal
dysfunction, injury and PARP activation were assessed.
Results. Incubation of proximal tubular cells with H2O2
caused a substantial increase in PARP activity, cellular in-
jury, and cell death, which were all significantly reduced in a
concentration-dependent by 5-AIQ [inhibitory concentration
50 (IC50) ∼ 0.03 mmol/L]. In vivo, renal I/R resulted in renal
dysfunction, injury, and PARP activation, primarily in the proxi-
mal tubules of the kidney. Administration of 5-AIQ significantly
reduced the biochemical and histologic signs of renal dysfunc-
tion and injury and markedly reduced PARP activation caused
by I/R.
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Conclusion. This study demonstrates that 5-AIQ is a potent,
water soluble inhibitor of PARP activity, which can significantly
reduce (1) cellular injury and death caused to primary cultures
of rat proximal tubular cells by oxidative stress in vitro, and (2)
renal injury and dysfunction caused by I/R of the kidney of the
rat in vivo.
Poly (adenosine 5′-diphosphate ribose) polymerase
[PARP, also known as poly (adenosine 5′-diphosphate
ribose) synthetase, (PARS), E.C. 2.4.2.30] is a ubiquitous,
chromatin-bound enzyme, which is abundantly present
in the nuclei of numerous cell types [1]. Activation
of PARP is triggered by single-strand breaks in DNA
and subsequently catalyses the transfer of adenosine
diphosphate (ADP)-ribose moieties from nicotinamide
adenosine dinucleotide (NAD)+ to various nuclear
proteins including histones and PARP itself (automodifi-
cation) [2]. Continuous or excessive activation of PARP
produces extended chains of ADP-ribose on nuclear
proteins and results in a substantial depletion of intracel-
lular NAD+ and subsequently, adenosine triphosphate
(ATP), leading to cellular dysfunction and ultimately, cell
death [3, 4]. Reactive oxygen or nitrogen species, such as
hydroxyl radicals and peroxynitrite, which are generated
during ischemia/reperfusion (I/R) and inflammation,
cause strand breaks in DNA, activate PARP, and deplete
NAD+ and ATP in cultured cells [5, 6]. Chemically
distinct inhibitors of PARP activity such as benza-
mides [e.g., 3-aminobenzamide (3-AB), nicotinamide]
and isoquinolinones [e.g., 1,5-dihydroxyisoquinoline
(5-hydroxyisoquinolin-1(2H)-one) (1,5-DHIQ), 3,4-
dihydro-5-(4-(1-piperidinyl)butoxyl)-1(2H)-
isoquinolinone), (DPQ)] can reduce the degree of
injury associated with I/R of the heart [7, 8], brain [9–11],
gut [12, 13], and skeletal muscle [7] and these investi-
gations have provided the basis for potential clinical
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applications of PARP inhibitors [14]. Furthermore, the
degree of tissue injury caused by I/R of the heart, brain
and gut is attenuated in mice in which the gene for PARP
has been disrupted by gene targeting (PARP knockout
or −/− mice) [13, 15–18].
Renal ischemia, whether caused by shock of different
etiologies, or during anesthesia, surgery,or transplanta-
tion, is a major cause of acute renal failure (ARF), which
despite significant advances in critical care medicine,
causes considerable morbidity and mortality that has not
decreased significantly over the last 50 years [19, 20]. The
prognosis of ARF is complicated by the fact that reper-
fusion, although essential for the survival of ischemic
renal tissue, causes additional damage (reperfusion in-
jury) [21]. Furthermore, the proximal tubule is particu-
larly susceptible to I/R injury, leading to acute tubular
necrosis (ATN), which plays a pivotal part in the patho-
genesis of ARF [21, 22]. Motivated by the fact that previ-
ous interventions against ARF have proved to be largely
negative and that dialysis still remains the only effective
therapy [23, 24], we have previously examined several
PARP inhibitors as potential novel therapeutic interven-
tions against I/R of the kidney and associated ARF [25].
Specifically, we have demonstrated that the chemically
distinct PARP inhibitors 3-AB and 1,5-DHIQ can at-
tenuate PARP activation and provide beneficial actions
against renal injury and dysfunction in in vivo and in vitro
models of renal I/R and oxidative stress [26, 27].
However, in contrast to isoquinolinone derivatives
such as 1,5-DHIQ and DPQ, 3-AB, and nicotinamide
are weak inhibitors of PARP activity that do not readily
cross cell membranes [5, 28]. Furthermore, although the
potency of recently developed PARP inhibitors has im-
proved greatly, most lack good solubility in water, making
it difficult to find a biocompatible vehicle for utilization
in vivo. Dimethylsulfoxide (DMSO) is often used as a
vehicle, however, DMSO itself is a potent scavenger of
hydroxyl radicals [29] and inhibits PARP activity [30] and
therefore it is not surprising that DMSO itself can reduce
organ injury in conditions in which I/R is implicated [31,
32]. Thus, there is still a great need for the development
of potent, water-soluble inhibitors of PARP activity.
Much effort has been made to develop new PARP
inhibitors with better potency, selectivity and water-
solubility and there are now 13 chemical classes of PARP
inhibitors [33]. Twelve years ago, Suto et al [34] used a
cell-free preparation of PARP (purified 900-fold from calf
thymus) to demonstrate that 5-aminoisoquinolinone [5-
aminoisoquinolin-1(2 H)-one] (5-AIQ) is a water-soluble
inhibitor of PARP activity. As previously published re-
ports of the synthesis of 5-AIQ reported problems of low
yield and unreliability [34, 35], we recently developed
a novel and more efficient method for the synthesis of
5-AIQ [36]. We have previously demonstrated that
5-AIQ can reduce I/R injury of the heart and liver [37,
38] and 5-AIQ has been shown to provide beneficial ef-
fects in rodent models of heart transplantation [39] and
lung injury [40]. Although there is evidence that 5-AIQ
can reduce the renal dysfunction caused by hemorrhagic
shock in the rat (which involves an element of renal I/R)
[36], there are, to our knowledge, no studies that have in-
vestigated the effects of 5-AIQ against direct I/R injury
of the kidney.
Our hypothesis was that this water-soluble (and there-
fore clinically applicable) PARP inhibitor could reduce
renal I/R injury, thereby ameliorating a major cause of
ischemic ARF. Therefore, having discovered that 5-AIQ
could reduce the renal dysfunction and cell death caused
by oxidative stress in primary cultures of rat proximal
tubular cells, we investigated the effects of the 5-AIQ
on the renal injury and dysfunction caused by I/R of the
kidneys of the anesthetized rat.
METHODS
Isolation and culture of rat proximal tubular cells
Proximal tubular cells were isolated from kidneys ob-
tained from 12 male Wistar rats (250 to 350 g) using colla-
genase digestion, differential sieving and Percoll density
centrifugation as described previously [26]. Rat proximal
tubular cells were cultured in minimum essential medium
(MEM) containing 10% (vol/vol) fetal calf serum (FCS)
in a humidified 5% CO2/95% air atmosphere at 37◦C
and medium was changed every 48 hours until the cells
reached confluence, which took between 7 and 10 days.
Proximal tubular cell cultures were used for experiments
upon reaching confluence.
In vitro experimental design
We have previously reported that exposure of rat prox-
imal tubular cells to hydrogen peroxide (H2O2) causes a
concentration-dependent (10 lmol/L to 10 mmol/L) and
time-dependent (1 to 6 hours) increase in cellular injury
and death, which is secondary to an increase in PARP ac-
tivity in these cells [26]. To elucidate the effects of 5-AIQ
on PARP activation, cellular injury and death caused
by H2O2, proximal tubular cells were preincubated
(10 minutes at 37◦C) with 5-AIQ (0.01 to 1 mmol/L) be-
fore incubation with H2O2 for 4 hours after which time
PARP activation, cellular injury, and cell death produced
by H2O2 were assessed.
Measurement of PARP activity (PARP assay)
We have previously reported that exposure of conflu-
ent primary cultures of rat proximal tubular cells to H2O2
causes a concentration-dependent (0.1 to 1 mmol/L) and
time-dependent (30 to 60 minutes) increase in PARP
activity, which is maximal 60 minutes after addition of
1 mmol/L H2O2 [26]. We therefore investigated the
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effect of 5-AIQ (0.01 to 1 mmol/L) on PARP activation
caused by 1 mmol/L H2O2 after 60 minutes’ incubation
as described previously [26]. Rat proximal tubular cells
were preincubated with 5-AIQ (0.01 to 1 mmol/L) for 10
minutes prior to the addition of H2O2. Proximal tubular
cells were incubated at 37◦C for 60 minutes after which
PARP activity was measured as described previously [26],
based on a protocol first described by Schraufstatter et al
in 1986 [41], which measures the ability of activated PARP
in permeablized cells to incorporate [3H] NAD onto nu-
clear proteins over a set time period. Briefly, incubation
medium was removed by aspiration and 400 lL MEM
added before the cells were scraped and transferred into
labeled microcentrifuge tubes. The cell suspension was
then centrifuged (10,500 rpm for 10 seconds) and the
pellet resuspended in 0.5 mL reaction buffer [consist-
ing of 56 mmol/L Hepes buffer containing 28 mmol/L
KCl, 28 mmol/L NaCl, 2 mmol/L MgCl2, 0.02% (wt/vol)
digitonin, and 125 nmol NAD spiked with 0.5 lCi/mL
[3H] NAD (specific activity 22 Ci/mmol) (NEN Life Sci-
ence Products, Ltd., Middlesex, UK), pH 7.5], previously
warmed to 37◦C. The mixtures were vortexed for 5 sec-
onds and incubated at 37◦C for 5 minutes. The reaction
was terminated by the addition of 200 lL of 50% (wt/vol)
trichloroacetic acid (TCA) and the samples vortexed and
centrifuged (10,500 rpm for 3 minutes). The resultant
protein precipitate pellet was washed twice using 50%
(wt/vol) TCA and solubilized overnight in 200 lL of a
0.5 mol/L NaOH and 2% (wt/vol) sodium dodecyl sul-
fate (SDS) mixture at 37◦C. The amount of [3H] NAD
incorporated into nuclear proteins was determined using
liquid scintillation counting and PARP activity expressed
as pmol NAD incorporated/well/min.
Measurement of cellular injury (MTT assay)
As previously described [26], cellular injury was
determined indirectly by measurement of the
mitochondrial-dependent conversion of MTT [3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide]
into a formazan, which unlike the tetrazolium salt,
can be measured spectrophotometrically at 550 nm.
Briefly, proximal tubular cells were incubated with
MTT [0.2 mg/mL in phosphate-buffered saline (PBS)
(0.01 mol/L, pH 7.4] for 1 hour at 37◦C after which the
MTT solution was removed by aspiration. The cells were
then solubilized in DMSO and an aliquot was transferred
into a 96-well plate after which the reduction of MTT
to formazan was quantified spectrophotometrically by
measurement of absorbance at 550 nm using an Anthos
Labtec microplate reader (Labtec, Uckfield, Sussex,
UK). Results were expressed as a percentage of the
mitochondrial respiration measured in control cells (i.e.,
those not exposed to H2O2), which was taken as 100%.
Measurement of cytotoxicity (LDH assay)
Cell death was determined by measurement of lac-
tate dehydrogenase (LDH) released into the incubation
medium due to the loss of membrane integrity using a
commercially available cytotoxicity detection kit (Roche
Diagnostics, Ltd., Lewes, East Sussex, UK) as previously
described [26]. Briefly, an aliquot of incubation medium
was transferred into a 96-well plate and reaction buffer
added to each well and the mixture was incubated for
30 minutes at room temperature. The reaction was
stopped by the addition of 2 mol/L HCl and absorbance
measured spectrophotometrically at 492 nm using an
Anthos Labtec Microplate Reader (Labtec). Results
were expressed as percentage of the total LDH released
from control cells (i.e., those not exposed to H2O2),
which were incubated with 1% (wt/vol) Triton X-100 for
30 minutes.
In vivo surgical procedure
In vivo studies were carried out using 40 male Wistar
rats (Tuck, Rayleigh, Essex, UK) weighing 220 to 320 g.
Rats received a standard diet and water ad libitum and
were cared for in accordance with the Home Office Guid-
ance in the Operation of the Animals (Scientific Proce-
dures) Act 1986, published by Her Majesty’s Stationery
Office, London, UK. All animals were anesthetized with
sodium thiopentone (Intraval Sodium, 120 mg/kg in-
traperitoneally) (Rhone Merieux, Ltd., Essex, UK) and
anesthesia was maintained by supplementary infusions
of sodium thiopentone. Rats were subjected to bilateral
renal ischemia for 45 minutes followed by reperfusion
for 6 hours as described previously [42]. Briefly, anes-
thetized rats were placed onto a thermostatically con-
trolled heating mat (Harvard Apparatus, Ltd., Kent, UK)
and body temperature maintained at 37 ± 1◦C by means
of a rectal probe attached to a homoeothermic blanket.
A tracheotomy was performed to maintain airway pa-
tency and to facilitate spontaneous respiration. The right
carotid artery was cannulated and connected to a pres-
sure transducer (Senso-Nor 840) (Horten, Norway) for
the measurement of mean arterial blood pressure (MAP)
and derivation of the heart rate from the pulse wave-
form, which were displayed on a data acquisition system
(MacLab 8e) (AD Instruments, Hastings, UK) installed
on a Dell Dimension 4100 computer. MAP and heart
rate were monitored for the duration of each experi-
ment. The jugular vein was cannulated for the admin-
istration of saline or anesthesia as required. A midline
laparotomy was performed and the bladder was cannu-
lated and allowed to drain freely without leakage into
the peritoneum. Both kidneys were located and the renal
pedicles, containing the artery, vein, and nerve supplying
each kidney, were carefully isolated.
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Rats were subjected to bilateral renal occlusion for
45 minutes using artery clips to clamp the renal pedi-
cles. Reperfusion commenced once the artery clips were
removed. Occlusion was verified visually by change in
the color of the kidneys to a paler shade, and reperfusion
by a blush. Other rats were subjected to sham-operation,
which underwent identical surgical procedures to con-
trol rats but did not undergo bilateral renal clamping
and were maintained under anesthesia for the duration
of the experiment. All groups described above received
a continuous infusion of 0.9% (wt/vol) saline or 5-AIQ
(2 mL/kg/hour intravenously) throughout the I/R period
and at the end of all experiments, rats were killed by an
overdose of sodium thiopentone.
Experimental groups
Upon completion of surgical procedures, rats were ran-
domly allocated into the following four groups: (1) I/R +
saline group rats were subjected to 45 minutes of re-
nal ischemia followed by reperfusion for 6 hours (N =
10) but were administered an intravenous bolus of saline
(2 mL/kg) 5 minutes before commencing reperfusion fol-
lowed by 2 mL/kg/hour throughout reperfusion; (2) I/R +
5-AIQ group were the same as the I/R + saline group
but in which rats were administered 5-AIQ as an in-
travenous bolus (0.3 mg/kg) 5 minutes prior to com-
mencing reperfusion followed by an intravenous infusion
(0.3 mg/kg/hour) throughout reperfusion (N = 10); (3)
sham + saline group rats were subjected to identical sur-
gical procedures as the above groups except for renal I/R,
and were maintained under anesthesia for the duration of
the experiment (45 minutes + 6 hours, N = 10), and which
were administered saline as an intravenous bolus and in-
fusion (2 mL/kg/hour) at time points equivalent to the
I/R groups; and (4) sham + 5-AIQ group were identical
to sham-operated rats except for the administration of
5-AIQ as an intravenous bolus (0.3 mg/kg) 5 minutes
prior to commencing reperfusion followed by an intra-
venous infusion (0.3 mg/kg/hour) throughout reperfusion
(N = 10).
The time course and doses of 5-AIQ, which was dis-
solved in saline, were based on those previously shown
by us, and others, to provide beneficial actions in the rat
[36–40].
Measurement of biochemical parameters
At the end of the reperfusion period, blood (1 mL)
samples were collected via the carotid artery into tubes
containing serum gel. The samples were centrifuged
(6000 rpm for 3 minutes) to separate serum. All
serum samples were analyzed for biochemical param-
eters within 24 hours after collection (Vetlab Services,
Sussex, UK). Serum levels of creatinine were used as in-
dicators of glomerular function [42]. Urine samples were
collected throughout the reperfusion period and the vol-
ume of urine produced recorded. Urine concentrations of
creatinine and Na+ were measured (Vetlab Services) and
used in conjunction with serum creatinine, Na+, and urine
flow to estimate creatinine clearance and fractional excre-
tion of Na+. Creatinine clearance provided an indication
of glomerular filtration rate and glomerular dysfunction
whereas fractional excretion of Na+ was used as an indi-
cator of tubular dysfunction [42]. Aspartate aminotrans-
ferase (AST), an enzyme located in the proximal tubule,
was used as an indicator of reperfusion-injury [42]. Addi-
tionally, urinary N-acetyl-b-D-glucosaminidase activity,
an indicator of tubular damage and possibly tubular func-
tion, was also measured (Clı´nica Me´dica e´ Diagno´stico,
Dr. Joaquim Chaves, Lisbon, Portugal) [42].
Histologic evaluation
Upon completion of experiments, kidneys were re-
moved and fixed in 10% (wt/vol) formaldehyde, buffered
with PBS, 0.01 mol/L, pH 7.4. For histologic evaluation
and scoring, a 5 mm section of kidney was removed and
processed through to wax after which 5 lm sections were
cut and stained with hematoxylin and eosin. A pathologist
blinded to the treatment received by each rat determined
histologic assessment of tubular necrosis semiquantita-
tively. Random cortical fields were observed using a ×20
objective. A graticule grid (25 squares) was used to deter-
mine the number of line intersects involving tubular pro-
files. One hundred intersections were examined for each
kidney and a score from 0 to 3 was given for each tubular
profile involving an intersection: 0, normal histology; 1,
tubular cell swelling, brush border loss, nuclear conden-
sation, with up to one third of tubular profile showing
nuclear loss; 2, as for score 1, but greater than one third
and less than two thirds of tubular profile shows nuclear
loss; and 3, greater than two thirds of tubular profile shows
nuclear loss. The total score for each kidney was calcu-
lated by addition of all 100 scores with a maximum score
of 300.
Immunohistochemical localization of poly (ADP-
ribose). Rat kidneys were fixed in 10% (wt/vol) neutral
buffered paraformaldehyde and 8 lm sections were pre-
pared from paraffin-embedded tissues. After deparaffina-
tion, endogenous peroxidase was quenched using 0.3%
(vol/vol) H2O2 in 60% (vol/vol) methanol for 30 min-
utes. The sections were permeablized using 0.1% (wt/vol)
Triton X-100 in PBS for 20 minutes. Nonspecific adsorp-
tion was minimized by incubating sections in 2% (vol/vol)
normal goat serum in PBS for 20 minutes. Endogenous
avidin and biotin binding sites were blocked by sequen-
tial incubation for 15 minutes with avidin (DBA, Milan,
Italy) and biotin (DBA), respectively. Kidney sections
were then used for the immunohistochemical localization
of poly (ADP-ribose) (PAR) as described previously [27].
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Briefly, poly (adenosine 5′-diphosphate ribose) (PAR)
(formed subsequent to PARP activation) was assessed
in sections after overnight incubation with a 1:500 di-
lution of primary anti-PAR rabbit polyclonal antibody
(DBA). Separate sections were also incubated with con-
trol solutions consisting of PBS alone or a 1:500 dilution
of nonspecific purified rabbit IgG (DBA). Specific label-
ing was detected using a biotin-conjugated goat antirabbit
IgG (DBA) and avidin-biotin peroxidase (DBA). Sam-
ples were then viewed under a light microscope.
Materials
Unless otherwise stated, all compounds used in this
study were purchased from Sigma-Aldrich Company,
Ltd. (Poole, Dorset, UK). All stock solutions were pre-
pared using nonpyrogenic saline [0.9% (wt/vol) NaCl;
Baxter Healthcare, Ltd., Thetford, Norfolk, UK].
Statistical analysis
All values described in the text and figures are ex-
pressed as mean ± standard error of the mean (se mean)
for N observations. For in vitro studies involving proxi-
mal tubular cells, measurements were taken from cultures
obtained from 12 separate isolations from 12 separate
rats. For the determination of PARP activation (PARP
assay), cellular injury (MTT assay) and cell death (LDH
assay), experiments were performed in triplicate. For in
vivo studies, each data point represents biochemical mea-
surements obtained from 10 separate animals in each
group. For histologic scoring, each data point represents
analysis of kidneys taken from six individual animals. For
immunohistochemical analysis, the figures shown are rep-
resentative of at least three experiments performed on
different experimental days. Statistical analysis was car-
ried out using GraphPad Prism 3.02/Instat 1.1 (GraphPad
Software, San Diego, CA, USA). Data were analyzed us-
ing one-way analysis of variance (ANOVA) followed by
Dunnett’s post hoc test and a P value of less than 0.05
was considered to be significant.
RESULTS
Isolation and cultures of rat proximal tubular cells
Isolation and primary culture of rat proximal tubular
cells resulted in confluent monolayers exhibiting typical
“cobblestone” morphology associated with epithelial
cells that did not exhibit any evidence of fibroblast
contamination.
Effect of 5-AIQ on PARP activation caused by H2O2
Exposure of rat proximal tubular cells to H2O2
(1 mmol/L for 1 hour) caused a twofold increase in PARP
activity (Fig. 1). This increase in PARP activity was at-
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Fig. 1. Effect of 5-aminoisoquinolinone (5-AIQ) (0.01 to 1 mmol/L)
(N = 12) on the increase in poly (ADP-ribose) (PARP) activity caused
by hydrogen peroxide (H2O2) (1 mmol/L for 1 hour) (N = 12) in rat
proximal tubular cells. 5-AIQ causes a concentration-dependent at-
tenuation of the increase in PARP activity caused by H2O2. Data are
expressed as mean ± SE mean of N observations. P < 0.05 when com-
pared with H2O2 only;P < 0.05 when compared with control proximal
tubular cells (untreated cells).
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Fig. 2. Effect of 5-aminoisoquinolinone (5-AIQ) (0.01 to 1 mmol/L)
(N = 12) on the impairment in mitochondrial respiration (MTT assay)
caused by hydrogen peroxide (H2O2) (1 mmol/L for 4 hours) (N = 12)
in rat proximal tubular cells. 5-AIQ causes a concentration-dependent
attenuation of the impairment in mitochondrial respiration caused by
H2O2. Data are expressed as mean ± SE mean of N observations.
P < 0.05 when compared with proximal tubular cells treated with H2O2
only.
tenuated in a concentration-dependent manner by pre-
treatment with 5-AIQ (IC50 ∼ 0.03 mmol/L) (Fig. 1).
Effects of 5-AIQ on the cellular injury and cell
death caused by H2O2
Incubation of rat proximal tubular cells with H2O2
(1 mmol/L for 4 hours) caused a substantial (∼ 80%)
reduction in mitochondrial respiration compared to
control (untreated) cells (Fig. 2). Pretreatment of
rat proximal tubular cells with 5-AIQ caused a
concentration-dependent attenuation of the impairment
in mitochondrial respiration caused by H2O2 (IC50 ∼
0.03 mmol/L) (Fig. 2). Incubation with H2O2 (1 mmol/L
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Fig. 3. Effect of 5-aminoisoquinolinone (5-AIQ) (0.01 to 1 mmol/L)
(N = 12) on the release of lactate dehydrogenase (LDH) from rat prox-
imal tubular cells caused by hydrogen peroxide (H2O2) (1 mmol/L for
4 hours) (N = 12). 5-AIQ causes a concentration-dependent reduction
of LDH release caused by H2O2. Data are expressed as mean ± SE
mean of N observations. P < 0.05 when compared with proximal tubu-
lar cells treated with H2O2 only; P < 0.05 when compared with control
proximal tubular cells (untreated cells).
for 4 hours) also caused a significant increase in LDH
release from rat proximal tubular cells, compared to con-
trol (untreated) cells (Fig. 3). Pretreatment with 5-AIQ
caused a concentration-dependent reduction in LDH re-
lease (IC50 ∼ 0.03 mmol/L) (Fig. 3).
In vivo studies
The mean ± SEM for the weights of the rats used in
this study was 260 ± 2 g (N = 40). On comparison with
sham animals, renal I/R produced significant increases in
serum, urinary, and histologic markers of renal dysfunc-
tion and injury as described in detail below (Figs. 4 to 9).
When compared to rats used as shams, renal I/R (in the
presence or absence of 5-AIQ) did not have a significant
effect on urine flow (0.017 ± 0.001 mL/min, N = 40).
Effect of 5-AIQ on renal dysfunction caused by I/R
Rat that underwent renal I/R exhibited significant
increases in the serum concentrations of creatinine
compared to sham-operated animals (Fig. 4) suggesting a
significant degree of glomerular dysfunction. This was re-
flected by a significant reduction in glomerular filtration
rate, which was measured as creatinine clearance (Fig. 5).
Compared to control animals (I/R + saline), administra-
tion of 5-AIQ (0.3 mg/kg) prior to and during reperfusion
produced a modest, but significant reduction in serum lev-
els of creatinine (Fig. 4). A similar profile was observed
in creatinine clearance with 5-AIQ (0.3 mg/kg) providing
a significant improvement (Fig. 5).
Effect of 5-AIQ on tubular dysfunction and injury
caused by renal I/R
Renal I/R produced a significant increase in fractional
excretion of Na+ (FENa) (Fig. 6) and urinary levels of
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Fig. 4. Effect of 5-aminoisoquinolinone (5-AIQ) on alterations in
serum levels of creatinine (glomerular dysfunction). Rats were sub-
jected to the surgical procedure alone and treated with saline (sham +
saline, N = 10) or 0.3 mg/kg 5-AIQ (sham + 5-AIQ, 0.3 mg/kg intra-
venous bolus 5 minutes prior to reperfusion followed by 0.3 mg/kg/hour
intravenous infusion throughout reperfusion, N = 10). Rats were also
subjected to ischemia/reperfusion (I/R) and treated with saline (I/R +
saline, N = 10) or with 0.3 mg/kg 5-AIQ (I/R + 5-AIQ, 0.3 mg/kg intra-
venous bolus 5 minutes prior to reperfusion followed by 0.3 mg/kg/hour
intravenous infusion throughout reperfusion, N = 10). Data are ex-
pressed as mean ± SE mean of N observations. P < 0.05 when com-
pared with I/R + saline group; P < 0.05 when compared sham + saline
group.
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Fig. 5. Effect of 5-aminoisoquinolinone (5-AIQ) on creatinine clear-
ance (glomerular filtration rate). Rats were subjected to the surgical
procedure alone and treated with saline (sham + saline, N = 10) or
0.3 mg/kg 5-AIQ (sham + 5-AIQ, 0.3 mg/kg intravenous bolus 5 min-
utes prior to reperfusion followed by 0.3 mg/kg/hour intravenous in-
fusion throughout reperfusion, N = 10). Rats were also subjected to
ischemia/reperfusion (I/R) and treated with saline (I/R + saline, N =
10) or with 0.3 mg/kg 5-AIQ (I/R + 5-AIQ, 0.3 mg/kg intravenous bolus
5 minutes prior to reperfusion followed by 0.3 mg/kg/hour intravenous
infusion throughout reperfusion, N = 10). Data are expressed as mean
± SE mean of N observations. P < 0.05 when compared with I/R +
saline group; P < 0.05 when compared sham + saline group.
NAG (Fig. 7), suggesting a marked increase in tubular
dysfunction and injury, respectively. On comparison with
FENa measured in control (I/R + saline) rats, administra-
tion of 5-AIQ (0.3 mg/kg) produced a significant reduc-
tion in the FENa measured after renal I/R, to levels that
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Fig. 6. Effect of 5-aminoisoquinolinone (5-AIQ) on alterations in
FENa (tubular dysfunction). Rats were subjected to the surgical pro-
cedure alone and treated with saline (sham + saline, N = 10) or 0.3
mg/kg 5-AIQ (sham + 5-AIQ, 0.3 mg/kg intravenous bolus 5 min-
utes prior to reperfusion followed by 0.3 mg/kg/hour intravenous in-
fusion throughout reperfusion, N = 10). Rats were also subjected to
ischemia/reperfusion (I/R) and treated with saline (I/R + saline, N =
10) or with 0.3 mg/kg 5-AIQ (I/R + 5-AIQ, 0.3 mg/kg intravenous bo-
lus 5 minutes prior to reperfusion followed by 0.3 mg/kg/hour intra-
venous infusion throughout reperfusion, N = 10). Data are expressed
as mean ± SE mean of N observations. P < 0.05 when compared with
I/R + saline group; P < 0.05 when compared sham + saline group.
were not significantly different from sham values (sham +
saline) (Fig. 6), suggesting marked improvement in tubu-
lar function. Administration of 5-AIQ (0.3 mg/kg) also
significantly reduced the increased urinary NAG levels
associated with renal I/R (Fig. 7), suggesting reduction of
tubular injury.
Effect of 5-AIQ on reperfusion injury caused
by renal I/R
On comparison with values obtained from sham-
operated animals, renal I/R produced significant
increases in serum concentrations of AST (suggesting sig-
nificant reperfusion-injury) (Fig. 8). Administration of
5-AIQ (0.3 mg/kg) prior to, and during reperfusion,
caused a significant attenuation of serum AST levels sub-
sequent to renal I/R (Fig. 8).
Effects of 5-AIQ on scoring of renal histopathology
On comparison with the total severity score measured
from kidneys obtained from sham-operated animals, re-
nal I/R produced a significant increase in total severity
score (Fig. 9). Administration of 5-AIQ (0.3 mg/kg) sig-
nificantly reduced the total severity score obtained from
kidneys subsequent to renal I/R when compared to that
obtained from rats subjected to renal I/R only (I/R +
saline)(Fig. 9).
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Fig. 7. Effect of 5-aminoisoquinolinone (5-AIQ) on alterations in uri-
nary NAG levels (tubular injury). Rats were subjected to the surgical
procedure alone and treated with saline (sham + saline, N = 10) or
0.3 mg/kg 5-AIQ (sham + 5-AIQ, 0.3 mg/kg intravenous bolus 5 min-
utes prior to reperfusion followed by 0.3 mg/kg/hour intravenous in-
fusion throughout reperfusion, N = 10). Rats were also subjected to
ischemia/reperfusion (I/R) and treated with saline (I/R + saline, N =
10) or with 0.3 mg/kg 5-AIQ (I/R + 5-AIQ, 0.3 mg/kg intravenous bolus
5 minutes prior to reperfusion followed by 0.3 mg/kg/hour intravenous
infusion throughout reperfusion, N = 10). Data are expressed as mean
± SE mean of N observations. P < 0.05 when compared with I/R +
saline group. P < 0.05 when compared sham + saline group.
Effect of 5-AIQ on PAR formation during renal I/R
Kidneys obtained from rats subjected to I/R demon-
strated marked staining for PAR formation when com-
pared with kidneys obtained from sham-operated rats
(Fig. 10A and B), suggesting PARP activation during
reperfusion. Kidneys obtained from rats administered
5-AIQ (0.3 mg/kg) demonstrated markedly reduced
staining for PAR (Fig. 10C) when compared with kidneys
obtained from rats subjected to renal I/R only, suggesting
a reduction in PARP activation during reperfusion.
DISCUSSION
We have recently reported a new, reliable and efficient
synthesis of 5-AIQ [36]. This method leads to a higher
yield of 5-AIQ than that previously reported [35]. Suto
et al [34] and Watson, Whish, and Threadgill [43] re-
ported an IC50 of 240 nmol/L when 5-AIQ was evaluated
in an in vitro cell free system consisting of PARP iso-
lated from calf thymus, which is broadly comparable with
other potent 5-substituted isoquinolinones. As 5-AIQ is
an analogue of the nicotinamide moiety of NAD+, it is
conceivable that it may also inhibit other ADP-ribosyl
transferases. We have previously examined the effect of
5-AIQ on the mono-ADP-ribosylating activity of
diphtheria toxin and found that it had an IC50 of approx-
imately 250 lmol/L, indicating a 1000-fold higher selec-
tivity for PARP [36].
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Fig. 8. Effect of 5-aminoisoquinolinone (5-AIQ) on alterations in
serum levels of aspartate aminotransferase (AST) (reperfusion-injury).
Rats were subjected to the surgical procedure alone and treated with
saline (sham + saline, N = 10) or 0.3 mg/kg 5-AIQ (sham + 5-AIQ,
0.3 mg/kg intravenous bolus 5 minutes prior to reperfusion followed by
0.3 mg/kg/hour intravenous infusion throughout reperfusion, N = 10).
Rats were also subjected to ischemia/reperfusion (I/R) and treated with
saline (I/R + saline, N = 10) or with 0.3 mg/kg 5-AIQ (I/R + 5-AIQ,
0.3 mg/kg intravenous bolus 5 minutes prior to reperfusion followed by
0.3 mg/kg/hour intravenous infusion throughout reperfusion, N = 10).
Data are expressed as mean ± SE mean of N observations. P < 0.05
when compared with I/R + saline group. P < 0.05 when compared
sham + saline group.
Armed with this encouraging potency and enzyme se-
lectivity in vitro and with the advantage of the high water-
solubility of 5-AIQ compared with other isoquinolinones,
we investigated the effects of this compound on PARP
activity in primary cultures of rat proximal tubular cells.
Exposure of rat proximal tubular cells to H2O2 (1 mmol/L
for 1 hour) resulted in a twofold increase in PARP activity.
This increase was attenuated by pretreatment of proximal
tubular cells with 5-AIQ in a concentration-dependent
fashion with an IC50 of approximately 0.03 mmol/L. These
findings demonstrate that 5-AIQ is a water-soluble and
potent inhibitor of PARP activity. When compared to
the benzamides 3-AB and nicotinamide and the iso-
quinolinone 1,5-DHIQ, 5-AIQ is the most potent (water-
soluble) inhibitor of PARP we have examined to date
[25–27, 32, 44, 45]. The effective concentration 50 (EC50)
of 5-AIQ for the prevention of the impairment in mito-
chondrial respiration and cell death caused by H2O2 was
identical (EC50 ∼ 0.03 mM) to the IC50 for the inhibi-
tion of PARP by 5-AIQ (IC50 ∼ 0.03 mmol/L), suggesting
that the prevention by 5-AIQ of the cell injury and death
caused by H2O2 in rat proximal tubular cells is due to the
inhibition of PARP activity in these cells.
In the next stage of this investigation, we investigated
the effects of 5-AIQ on the renal dysfunction and injury
caused by I/R of the kidney of the anesthetized rat. We
have reported previously that the model of renal I/R used
here results in the glomerular and tubular dysfunction
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Fig. 9. Effect of 5-aminoisoquinolinone (5-AIQ) on total severity score
(histologic assessment of renal injury). Rats were subjected to the sur-
gical procedure alone and treated with saline (sham + saline, N =
6) or 0.3 mg/kg 5-AIQ (sham + 5-AIQ, 0.3 mg/kg intravenous bolus
5 minutes prior to reperfusion followed by 0.3 mg/kg/hour intraveneous
infusion throughout reperfusion, N = 6). Rats were also subjected to
ischemia/reperfusion (I/R) and treated with saline (I/R + saline, N =
6) or with 0.3 mg/kg 5-AIQ (I/R + 5-AIQ, 0.3 mg/kg intravenous bolus
5 minutes prior to reperfusion followed by 0.3 mg/kg/hour intravenous
infusion throughout reperfusion, N = 6). Data are expressed as mean
± SE mean of N observations. P < 0.05 when compared with I/R +
saline group; P < 0.05 when compared to sham + saline group.
and injury associated with I/R as well as the classical his-
tologic signs of renal injury, which included recognized
features of acute tubular damage such as loss of brush
border, nuclear condensation, cytoplasmic swelling, and
consistent loss of significant numbers of nuclei from tubu-
lar profiles. We report here that 5-AIQ causes a modest,
but significant, reduction in glomerular dysfunction (as
assessed by measurement of serum creatinine levels and
by assessment of creatinine clearance). However, the ef-
fect of 5-AIQ on tubular dysfunction (as determined by
estimation of FENa) is more pronounced, causing FENa
be reduced to levels not significantly different to those
obtained from sham-operated rats. This greater effect of
5-AIQ on tubular function is not surprising given that im-
munohistochemical localization of PARP in rat kidney in
this and previous studies demonstrate its localization to
the proximal tubule [27] and that PARP inhibitors can
protect rat proximal tubular cells against oxidative stress
[26]. 5-AIQ also significantly reduced both the tubular
injury (urinary NAG levels) and reperfusion injury (AST
levels) associated with renal I/R. However, it should be
noted although 5-AIQ had a greater effect on tubular dys-
function and injury than glomerular dysfunction, and that
the proximal tubular is at most risk of injury caused by
renal I/R or oxidative stress [26, 27, 42], there was still ev-
idence of renal injury, highlighting the fact that the mech-
anisms involved in the development of ischemic ARF are
multifactorial (e.g., I/R also leads to detrimental increases
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Fig. 10. Immunohistochemical localization of PAR in sections of rat
kidney; (A) sham-operated group, (B) ischemia/reperfusion (I/R)+
in intracellular Ca2+ concentrations and calpain/caspase
activation [19–22]). Furthermore, the measurement of re-
nal function has inherent difficulties (e.g., a one point in
time serum creatinine is not a particularly reliable indi-
cator, especially when changes are rather modest) and
therefore these measurements (especially measurement
of glomerular dysfunction) may not have revealed the full
beneficial effects of PARP inhibition by 5-AIQ.
One could argue that some proportion of the ability of
5-AIQ to reduce renal injury in vivo and in vitro could be
due to scavenging of reactive oxygen species (ROS). In-
deed, the PARP inhibitors 3-AB and nicotinamide have
been reported to possess ROS scavenging properties [46–
48]. However, at concentrations below 10 mmol/L, 3-AB,
nicotinamide, and 1,5-DHIQ (which being an isoquinoli-
none derivative has a similar chemical structure and prop-
erties as 5-AIQ) do not scavenge ROS [44]. This notion is
supported by the finding that these agents are unable to
attenuate the development of single-strand breaks in the
DNA of rat proximal tubular cells and other cell types
caused by ROS [26, 44].
3-AB is a relatively weak PARP inhibitor that does
not readily cross cell membranes [5, 28]. Although 1,5-
DHIQ and DPQ are more potent PARP inhibitors than
3-AB, both 1,5-DHIQ and DPQ have to be dissolved in
DMSO. This potentially causes several problems as (1)
DMSO itself is a potent scavenger of hydroxyl radicals
[29] and (2) DMSO itself inhibits PARP activity [30].
Thus, it is not surprising that DMSO per se can reduce the
organ injury associated with I/R [31, 32]. Thus, due to its
water-solubility (as well as its potency), 5-AIQ currently
represents the best pharmacologic tool with which to elu-
cidate the role of PARP in the pathophysiology of I/R and
other disease states [49]. In contrast to “prototypical” or
“classical” PARP inhibitors such as benzamide analogues
that have been available for over 20 years, there is cur-
rently a dearth of information available on the selectiv-
ity and potential side-effects of more recently developed
and potent PARP inhibitors such as the isoquinolinones
[5]. Although it has been established that 5-AIQ displays
1000-fold selectivity for PARP over mono(ADP-ribosyl)
transferase [36], the effects of 5-AIQ on other enzymes
has not been established. Furthermore, only limited
saline group and (C) I/R with administration of 0.3 mg/kg 5-
aminoisoquinolinone (5-AIQ) (0.3 mg/kg intravenous bolus 5 minutes
prior to reperfusion followed by 0.3 mg/kg/hour intravenous infusion
throughout reperfusion). Sections were incubated overnight at 4◦C
with primary mouse antirat monoclonal antibody directed at PAR
[1:500 (vol/vol) in phosphate-buffered saline (PBS)]. Specific labeling
of antigen-antibody complex was visualized using an avidin-biotin per-
oxidase complex immunoperoxidase technique using chromogen di-
aminobenzidine. Arrows indicate localization of PAR, predominantly
to proximal tubular cells. Figures shown are representative of at least
three experiments performed on different experimental days (magnifi-
cation ×125).
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pharmacodynamic and pharmacokinetic data exist for
these novel PARP inhibitors and, therefore, appropriate
caution should be used in experimental design and in the
interpretation of data obtained using compounds such as
5-AIQ.
CONCLUSION
We have used 5-AIQ, a novel, potent and water-soluble
inhibitor of PARP activity, to show that (1) PARP acti-
vation contributes to the renal injury caused by oxidative
stress and I/R and (2) that 5-AIQ can reduce the cellular
injury and death of renal cells caused by oxidative stress
(in vitro) and the renal dysfunction and injury caused by
I/R of the rat kidney (in vivo). Our results support the hy-
pothesis that inhibitors of PARP activity may be useful
in conditions associated with I/R [5, 6, 14, 49, 50].
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